Patient Preferences in Moderate-to-Severe Atopic Dermatitis (AD): A Discrete Choice Experiment (DCE)

Main Article Content

Steven R. Feldman
Wake Forest University School of Medicine

Annie Guerin
Analysis Group, Inc., Montreal, QC, Canada

Marjolaine Gauthier-Loiselle
Analysis Group, Inc., Montreal, QC, Canada

Ami J Claxton
LEO Pharma, Madison, NJ, USA

Nisha C Hazra
Analysis Group, Inc., London, UK

Yan Meng
Analysis Group, Inc., London, UK

Kirsten Gallant
Analysis Group, Inc., London, UK

Sanjeev Balu
LEO Pharma, Madison, NJ, USA

Keywords

atopic dermatitis, patient preferences, drug attributes, discrete choice experiment

References

1. Silverberg, J.I., et al., Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Annals of Allergy, Asthma & Immunology, 2018. 121(3): p. 340-347.

2. Ervin, C., et al., Patient and caregiver preferences on treatment attributes for atopic dermatitis. Journal of Dermatological Treatment, 2022. 33(4): p. 2225-2233

3. DiBonaventura Md, et al., The burden of chronic obstructive pulmonary disease among employed adults. International Journal of Chronic Obstructive Pulmonary Disease., 2012. 7: p. 211-219.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.284

Article Details

How to Cite
[1]
Feldman, S.R. , Guerin, A. , Gauthier-Loiselle, M. , Claxton, A.J. , Hazra, N.C., Meng, Y., Gallant, K. and Balu, S. 2023. Patient Preferences in Moderate-to-Severe Atopic Dermatitis (AD): A Discrete Choice Experiment (DCE). SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s284. DOI:https://doi.org/10.25251/skin.7.supp.284.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)